ADX71743

Error creating thumbnail:

ADX71743.svg

== ADX71743 ==

ADX71743 is a pharmacological compound that acts as a selective positive allosteric modulator of the metabotropic glutamate receptor 7 (mGluR7). It has been studied for its potential therapeutic effects in various neurological disorders.

Mechanism of Action

ADX71743 functions by binding to the allosteric site of the mGluR7 receptor, enhancing its response to the neurotransmitter glutamate. This modulation can influence synaptic transmission and neuroplasticity, which are critical processes in the central nervous system.

Therapeutic Potential

Research has indicated that ADX71743 may have potential applications in the treatment of anxiety disorders, depression, and epilepsy. By modulating mGluR7 activity, it may help to restore normal neurotransmitter balance and alleviate symptoms associated with these conditions.

Pharmacokinetics

The pharmacokinetic profile of ADX71743 includes its absorption, distribution, metabolism, and excretion. Detailed studies are required to fully understand its bioavailability and half-life in the human body.

Research and Development

ADX71743 is currently under investigation in preclinical and clinical trials. Its efficacy and safety profile are being evaluated to determine its potential as a therapeutic agent.

Related Compounds

Other compounds that act on metabotropic glutamate receptors include LY354740, MPEP, and PHCCC. These compounds have varying effects on different subtypes of mGluRs and are also being studied for their therapeutic potential.

See Also

• Metabotropic glutamate receptor
• Allosteric modulator
• Neurotransmitter
• Synaptic transmission
• Neuroplasticity